Progress in clinical neurosciences: a forum on the early management of Parkinson's disease.
There are numerous concerns related to treatment choices involving early dopaminergic therapy in Parkinson's disease. These include the effect on the underlying progression of the neurodegenerative process as well as the development of motor complications such as fluctuations and dyskinesias. A number of recent basic and clinical studies have provided new insights but have also added confusion and controversy. This report summarizes presentations and discussion dealing with these issues from a one-day symposium involving Canadian Movement Disorders neurologists.
Lang
Anthony E
AE
Division of Neurology, Department of Medicine, University of Toronto, Toronto Western Hospital, Canada.
Miyasaki
Janis
J
Olanow
C Warren
CW
Stoessl
A Jon
AJ
Suchowersky
Oksana
O
D000978:Antiparkinson Agents / Q000627:therapeutic use; D018491:Dopamine Agonists / Q000627:therapeutic use; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D009069:Movement Disorders / Q000209:etiology / Q000628:therapy; D010300:Parkinson Disease / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*
D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D007980:Levodopa